Research programme: matrix metalloproteinase-13 inhibitors - Alantos
Latest Information Update: 08 Sep 2008
At a glance
- Originator Alantos Pharmaceuticals
- Class Small molecules
- Mechanism of Action Matrix metalloproteinase 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 08 Sep 2008 Discontinued - Preclinical for Osteoarthritis in USA (PO)
- 08 Sep 2008 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
- 17 Jul 2007 Alantos has been acquired by Amgen